Braveheart Bio Prices Upsized Initial Public Offering on Nasdaq at $18 per Share

MT Newswires Live

Aug 06

Braveheart Bio (BRVE) priced its upsized initial public offering of approximately 21.3 million shares at $18 per share, the company said late Wednesday.

All shares in the offering are being sold by Braveheart Bio.

The shares are expected to start trading on the Nasdaq Global Market on Thursday under the ticker symbol BRVE. Braveheart Bio said the offering is expected to close on Friday.

The company said it also granted the underwriters a 30-day option to purchase up to an additional 3.2 million shares at the IPO price.

Braveheart Bio expects to generate approximately $382.5 million in gross proceeds from the offering.

Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor are acting as joint book-running managers.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2657681246"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2657681246\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2657681246?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 17:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657681246","market":"hk","top_or_hot":-1,"title":"Braveheart Bio Prices Upsized Initial Public Offering on Nasdaq at $18 per Share","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/BRVE\">Braveheart Bio</a> (BRVE) priced its upsized initial public offering of approximately 21.3 million shares at $18 per share, the company said late Wednesday.</p><p>All shares in the offering are being sold by Braveheart Bio.</p><p>The shares are expected to start trading on the Nasdaq Global Market on Thursday under the ticker symbol BRVE. Braveheart Bio said the offering is expected to close on Friday.</p><p>The company said it also granted the underwriters a 30-day option to purchase up to an additional 3.2 million shares at the IPO price.</p><p>Braveheart Bio expects to generate approximately $382.5 million in gross proceeds from the offering.</p><p>Goldman Sachs, Jefferies, TD Cowen, <a href=\"https://laohu8.com/S/SFB\">Stifel</a>, and Cantor are acting as joint book-running managers.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Braveheart Bio Prices Upsized Initial Public Offering on Nasdaq at $18 per Share</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBraveheart Bio Prices Upsized Initial Public Offering on Nasdaq at $18 per Share\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-06 17:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/BRVE\">Braveheart Bio</a> (BRVE) priced its upsized initial public offering of approximately 21.3 million shares at $18 per share, the company said late Wednesday.</p><p>All shares in the offering are being sold by Braveheart Bio.</p><p>The shares are expected to start trading on the Nasdaq Global Market on Thursday under the ticker symbol BRVE. Braveheart Bio said the offering is expected to close on Friday.</p><p>The company said it also granted the underwriters a 30-day option to purchase up to an additional 3.2 million shares at the IPO price.</p><p>Braveheart Bio expects to generate approximately $382.5 million in gross proceeds from the offering.</p><p>Goldman Sachs, Jefferies, TD Cowen, <a href=\"https://laohu8.com/S/SFB\">Stifel</a>, and Cantor are acting as joint book-running managers.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2657681246","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2657681246","pubTimestamp":1786009378,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Braveheart Bio  priced its upsized initial public offering of approximately 21.3 million shares at $18 per share, the company said late Wednesday.All shares in the offering are being sold by Braveheart Bio.The shares are expected to start trading on the Nasdaq Global Market on Thursday under the ticker symbol BRVE. Braveheart Bio said the offering is expected to close on Friday.The company said it also granted the underwriters a 30-day option to purchase up to an additional 3.2 million shares at the IPO price.Braveheart Bio expects to generate approximately $382.5 million in gross proceeds from the offering.Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor are acting as joint book-running managers.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPOS":"Renaissance International IPO ETF","BRVE":"Braveheart Bio","LCLG":"Logan Capital Broad Innovative Growth ETF"},"translate_title":"Braveheart Bio 将纳斯达克首次公开募股价格提高至每股 18 美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NQmain":1.5,"BRVE":1.5,"IPOS":1.5,"LCLG":1.5},"content_text":"Braveheart Bio (BRVE) priced its upsized initial public offering of approximately 21.3 million shares at $18 per share, the company said late Wednesday.All shares in the offering are being sold by Braveheart Bio.The shares are expected to start trading on the Nasdaq Global Market on Thursday under the ticker symbol BRVE. Braveheart Bio said the offering is expected to close on Friday.The company said it also granted the underwriters a 30-day option to purchase up to an additional 3.2 million shares at the IPO price.Braveheart Bio expects to generate approximately $382.5 million in gross proceeds from the offering.Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor are acting as joint book-running managers.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}